We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PMC Board Continues to Cultivate Leadership from Across Health Care System
News

PMC Board Continues to Cultivate Leadership from Across Health Care System

PMC Board Continues to Cultivate Leadership from Across Health Care System
News

PMC Board Continues to Cultivate Leadership from Across Health Care System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PMC Board Continues to Cultivate Leadership from Across Health Care System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Continuing to convene leaders in personalized medicine from across the health care system, the Personalized Medicine Coalition (PMC) has announced the election of two representatives from both the diagnostic and pharmaceutical industries to its Board of Directors: Genomic Health Chairman of the Board, CEO and President, Kim Popovits and Pfizer Executive Director and Head of Diagnostics, Hakan Sakul, Ph.D.

“The additional representation from the diagnostic and pharmaceutical communities further strengthens PMC’s ability to engage all of the stakeholders in health care so that they can work together to develop consensus solutions to the challenges facing the field,” said PMC President Edward Abrahams, Ph.D. “The future of personalized medicine depends on collaboration among multiple sectors.”

In her role at Genomic Health, Popovits leads the company’s efforts to revolutionize the treatment of cancer care through genomic tests for breast, colon and prostate cancers, as well as a pipeline of liquid biopsy tests.

“PMC has been at the forefront of advocating on behalf of innovators, researchers, patients and physicians, and I am delighted to join the Board to help lead the national discussion around advancing the adoption of personalized medicine through public policy,” she said.

Sakul leads Pfizer’s efforts in companion diagnostics across Pfizer’s pharmaceutical pipeline. His work has resulted in several companion diagnostic partnerships, including the initiative that led to the simultaneous FDA approvals of Xalkori (crizotinib) and its companion diagnostic in 2011.

“As a founding member, Pfizer has been active in PMC for more than 10 years,” Sakul said. “As a new Board member, I am delighted to work closer with the PMC staff and my fellow PMC Board members to help advance personalized medicine.”

The appointments coincide with the expiring terms of Felix Frueh, Ph.D., Human Longevity and Jeffrey Cossman, M.D., formerly of United States Diagnostic Standards.

Advertisement